Illumina - ILMN Stock Price Target and Predictions

Target and Analyst Ratings
Price Target History
Upgrades and Downgrades
News Sentiment
About
FAQ

Consensus Rating: Hold
Consensus Price Target: $167.70
Forecasted Upside: 43.71%
Number of Analysts: 19
Breakdown:
2 Sell Ratings
9 Hold Ratings
8 Buy Ratings
0 Strong Buy Ratings

^$116.69 As of 04/18/2024 01:00 AM ET

▼ -1.6 (-1.35%)

1 month | 3 months | 12 months

Get New Illumina Analyst Ratings Delivered To Your Inbox

Sign-up to receive the latest news and ratings for ILMN and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ILMN

^$167.70

▲ +43.71% Upside Potential

This price target is based on 19 analysts offering 12 month price targets for Illumina in the last 3 months. The average price target is $167.70, with a high forecast of $253.00 and a low forecast of $100.00. The average price target represents a 43.71% upside from the last price of $116.69.

Current Consensus is Hold

The current consensus among 19 polled investment analysts is to hold stock in Illumina. This Hold consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

0 strong buy ratings
8 buy ratings
9 hold ratings
2 sell ratings

Ratings as of

10/26/2022

0 strong buy ratings
8 buy ratings
9 hold ratings
2 sell ratings

Ratings as of

1/24/2023

0 strong buy ratings
8 buy ratings
9 hold ratings
2 sell ratings

Ratings as of

4/24/2023

0 strong buy ratings
8 buy ratings
9 hold ratings
2 sell ratings

Ratings as of

7/23/2023

0 strong buy ratings
8 buy ratings
9 hold ratings
2 sell ratings

Ratings as of

10/21/2023

0 strong buy ratings
8 buy ratings
9 hold ratings
2 sell ratings

Ratings as of

1/19/2024

0 strong buy ratings
8 buy ratings
9 hold ratings
2 sell ratings

Ratings as of

3/19/2024

0 strong buy ratings
8 buy ratings
9 hold ratings
2 sell ratings

Ratings as of

4/18/2024

Latest Recommendations

Show Most Recent Rating from Each Ratings Firm Show All Ratings

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price
4/10/2024	Barclays	Boost Target	Underweight ➝ Underweight	$85.00 ➝ $100.00	Low
4/10/2024	Stephens	Reiterated Rating	Overweight ➝ Overweight	$170.00	Low
4/9/2024	Royal Bank of Canada	Reiterated Rating	Outperform ➝ Outperform	$253.00	Low
3/20/2024	OTR Global	Reiterated Rating	Positive ➝ Mixed		Low
2/14/2024	Stephens	Reiterated Rating	Overweight ➝ Overweight	$170.00	Low
2/9/2024	Royal Bank of Canada	Reiterated Rating	Outperform ➝ Outperform	$258.00	Low
1/25/2024	Barclays	Boost Target	Underweight ➝ Underweight	$50.00 ➝ $80.00	Low
1/16/2024	HSBC	Downgrade	Buy ➝ Hold		Low
1/4/2024	TD Cowen	Downgrade	Outperform ➝ Market Perform	$144.00	Low
12/19/2023	Royal Bank of Canada	Lower Target	Outperform ➝ Outperform	$260.00 ➝ $258.00	Low
12/18/2023	Scotiabank	Upgrade	Sector Perform ➝ Sector Outperform	$185.00	Low
12/15/2023	Sanford C. Bernstein	Upgrade	Underperform ➝ Market Perform		Low
12/14/2023	Stephens	Initiated Coverage	Overweight	$170.00	Low
12/14/2023	Guggenheim	Initiated Coverage	Buy	$155.00	Low
12/13/2023	Wolfe Research	Initiated Coverage	Outperform	$175.00	Low
12/12/2023	Bank of America	Downgrade	Neutral ➝ Underperform	$140.00 ➝ $100.00	Low
12/11/2023	Citigroup	Upgrade	Sell ➝ Neutral	$85.00 ➝ $120.00	Low
11/13/2023	Piper Sandler	Lower Target	Overweight ➝ Overweight	$200.00 ➝ $190.00	Low
11/10/2023	Canaccord Genuity Group	Reiterated Rating	Buy ➝ Hold	$210.00 ➝ $120.00	Low
11/10/2023	Canaccord Genuity Group	Downgrade	Buy ➝ Hold	$210.00 ➝ $120.00	Low
10/16/2023	Piper Sandler	Lower Target	Overweight ➝ Overweight	$275.00 ➝ $200.00	Low
10/12/2023	Stifel Nicolaus	Reiterated Rating	Buy ➝ Buy	$200.00	Low
9/29/2023	Stifel Nicolaus	Lower Target	Buy ➝ Buy	$225.00 ➝ $200.00	Low
9/29/2023	Barclays	Lower Target	Underweight ➝ Underweight	$150.00 ➝ $100.00	Low
9/29/2023	HSBC	Lower Target		$230.00 ➝ $171.00	Low
9/28/2023	Sanford C. Bernstein	Initiated Coverage	Underperform	$111.00	Low
9/1/2023	Evercore ISI	Reiterated Rating	Outperform ➝ Outperform	$240.00	Low
8/16/2023	Canaccord Genuity Group	Lower Target	Buy ➝ Buy	$300.00 ➝ $285.00	Low
8/15/2023	Piper Sandler	Lower Target	Overweight ➝ Overweight	$290.00 ➝ $275.00	Low
8/14/2023	HSBC	Lower Target	Buy ➝ Buy	$270.00 ➝ $235.00	Low
8/10/2023	JPMorgan Chase & Co.	Lower Target	Neutral ➝ Neutral	$235.00 ➝ $190.00	Low
8/10/2023	Evercore ISI	Boost Target	Outperform ➝ Outperform	$235.00 ➝ $240.00	Low
8/10/2023	Stifel Nicolaus	Lower Target	Buy ➝ Buy	$265.00 ➝ $225.00	N/A
8/10/2023	Bank of America	Lower Target		$230.00 ➝ $210.00	Low
8/10/2023	Citigroup	Lower Target	Sell ➝ Sell	$180.00 ➝ $150.00	Low
8/10/2023	Credit Suisse Group	Lower Target	Neutral ➝ Neutral	$225.00 ➝ $200.00	Low
8/10/2023	Robert W. Baird	Lower Target		$229.00 ➝ $180.00	Low
8/8/2023	UBS Group	Lower Target	Neutral ➝ Neutral	$240.00 ➝ $230.00	Low
8/8/2023	Royal Bank of Canada	Lower Target	Outperform ➝ Outperform	$337.00 ➝ $328.00	Low
4/26/2023	Stifel Nicolaus	Boost Target		$235.00 ➝ $265.00	Low
4/26/2023	Robert W. Baird	Boost Target		$224.00 ➝ $229.00	Low
4/14/2023	Royal Bank of Canada	Boost Target	Outperform	$300.00 ➝ $337.00	Low
3/15/2023	Royal Bank of Canada	Lower Target	Outperform	$303.00 ➝ $300.00	Low
2/14/2023	UBS Group	Lower Target	Neutral	$255.00 ➝ $240.00	Low
2/8/2023	Piper Sandler	Reiterated Rating	Overweight	$290.00	Low
2/8/2023	Stifel Nicolaus	Lower Target		$285.00 ➝ $235.00	Low
2/8/2023	JPMorgan Chase & Co.	Lower Target	Neutral	$300.00 ➝ $271.00	Low
2/8/2023	Royal Bank of Canada	Boost Target	Outperform	$284.00 ➝ $303.00	Low
2/8/2023	Bank of America	Boost Target		$210.00 ➝ $230.00	Low
2/8/2023	SVB Leerink	Boost Target	Outperform	$249.00 ➝ $250.00	Low
2/8/2023	Barclays	Lower Target	Underweight	$160.00 ➝ $150.00	Low
1/27/2023	Piper Sandler	Lower Target		$300.00 ➝ $290.00	Low
1/25/2023	Argus	Downgrade	Buy ➝ Hold		Low
1/17/2023	Canaccord Genuity Group	Lower Target	Buy	$330.00 ➝ $300.00	Low
1/10/2023	Bank of America	Lower Target		$220.00 ➝ $210.00	Low
1/10/2023	Cowen	Lower Target		$350.00 ➝ $296.00	Low
1/4/2023	Scotiabank	Initiated Coverage	Sector Perform	$216.00	Low
12/20/2022	OTR Global	Upgrade	Mixed ➝ Positive		Low
12/12/2022	Citigroup	Downgrade	Neutral ➝ Sell	$200.00 ➝ $180.00	Low
12/6/2022	Royal Bank of Canada	Initiated Coverage	Outperform	$282.00	Low
11/14/2022	Piper Sandler	Lower Target	Overweight	$320.00 ➝ $300.00	Low
11/7/2022	Morgan Stanley	Lower Target	Equal Weight	$240.00 ➝ $225.00	Low
11/4/2022	Canaccord Genuity Group	Lower Target	Buy ➝ Buy	$340.00 ➝ $330.00	Low
11/4/2022	Cowen	Boost Target		$327.00 ➝ $350.00	Low
11/4/2022	Credit Suisse Group	Lower Target	Neutral	$230.00 ➝ $225.00	N/A
11/4/2022	Cowen	Boost Target		$327.00 ➝ $350.00	Low
11/4/2022	Robert W. Baird	Lower Target		$215.00 ➝ $210.00	Low
10/11/2022	Argus	Lower Target		$300.00 ➝ $250.00	Low
10/4/2022	SVB Leerink	Upgrade	Market Perform ➝ Outperform	$220.00 ➝ $270.00	Low
9/30/2022	Barclays	Boost Target	Underweight	$130.00 ➝ $175.00	Low
9/28/2022	OTR Global	Downgrade	Positive		Low
9/28/2022	Evercore ISI	Upgrade	In-Line ➝ Outperform	$170.00 ➝ $250.00	Low
8/24/2022	Credit Suisse Group	Initiated Coverage	Neutral	$230.00	Low
8/17/2022	UBS Group	Lower Target	Neutral	$350.00 ➝ $245.00	Low
8/15/2022	Evercore ISI	Lower Target		$170.00	N/A
8/15/2022	Cowen	Lower Target		$327.00	N/A
8/15/2022	Barclays	Lower Target		$130.00	N/A
8/15/2022	Atlantic Securities	Lower Target		$190.00	N/A
8/12/2022	Morgan Stanley	Lower Target	Equal Weight	$350.00 ➝ $240.00	Low
8/12/2022	Bank of America	Lower Target		$220.00 ➝ $200.00	Low
8/12/2022	Piper Sandler	Lower Target	Overweight	$360.00 ➝ $320.00	Low
8/12/2022	Canaccord Genuity Group	Lower Target	Buy ➝ Buy	$450.00 ➝ $380.00	Low
8/12/2022	SVB Leerink	Lower Target	Market Perform	$225.00 ➝ $220.00	Low
8/12/2022	Stifel Nicolaus	Lower Target	Buy	$480.00 ➝ $300.00	Low
8/12/2022	Citigroup	Lower Target	Neutral	$220.00 ➝ $200.00	Low
8/12/2022	Robert W. Baird	Lower Target		$306.00 ➝ $215.00	Low
7/19/2022	Cowen	Set Target		$412.00	Low
7/13/2022	Barclays	Downgrade	Equal Weight ➝ Underweight	$350.00 ➝ $150.00	N/A
7/8/2022	Citigroup	Lower Target	Neutral	$325.00 ➝ $220.00	N/A
5/15/2022	Piper Sandler	Lower Target	NA	$460.00 ➝ $360.00	Low
5/6/2022	Canaccord Genuity Group	Lower Target	Buy ➝ Buy	$555.00 ➝ $520.00	High
5/6/2022	Cowen	Lower Target		$506.00 ➝ $492.00	High
5/6/2022	Cowen	Lower Target		$506.00 ➝ $492.00	High
5/6/2022	Citigroup	Lower Target		$400.00 ➝ $325.00	High
3/29/2022	OTR Global	Upgrade	Mixed ➝ Positive		Medium
2/15/2022	Piper Sandler	Boost Target	Overweight	$450.00 ➝ $460.00	Medium
2/11/2022	Robert W. Baird	Lower Target		$437.00 ➝ $380.00	High
2/11/2022	SVB Leerink	Lower Target	Market Perform	$430.00 ➝ $400.00	High
1/18/2022	Stifel Nicolaus	Upgrade	Hold ➝ Buy	$480.00	High
1/11/2022	Barclays	Upgrade	Underweight ➝ Equal Weight	$432.72 ➝ $412.00	High
1/11/2022	SVB Leerink	Boost Target	Market Perform	$420.00 ➝ $430.00	High
1/10/2022	Barclays	Lower Target	Underweight	$365.00 ➝ $350.00	High
1/7/2022	Bank of America	Upgrade	Underperform ➝ Neutral	$390.00	High
1/6/2022	Citigroup	Lower Target	Neutral ➝ Neutral	$450.00 ➝ $400.00	High
1/6/2022	Morgan Stanley	Initiated Coverage	Neutral ➝ Equal Weight	$425.00	High
11/8/2021	Robert W. Baird	Lower Target	Neutral	$493.00 ➝ $437.00	High
10/19/2021	SVB Leerink	Lower Target	Market Perform	$425.00 ➝ $420.00	Low
8/22/2021	Robert W. Baird	Reiterated Rating	Hold		Medium
8/19/2021	SVB Leerink	Downgrade	Outperform ➝ Market Perform	$425.00	High
8/6/2021	Barclays	Boost Target	Underweight	$355.00 ➝ $365.00	Low
8/6/2021	Piper Sandler	Boost Target	Overweight	$510.00 ➝ $560.00	High
7/29/2021	SVB Leerink	Reiterated Rating	Buy		Low
7/13/2021	Barclays	Boost Target	Underweight	$300.00 ➝ $355.00	Low
4/28/2021	Wells Fargo & Company	Boost Target	Underweight	$330.00 ➝ $340.00	High
4/6/2021	Wells Fargo & Company	Boost Target	Underweight	$300.00 ➝ $330.00	Medium
3/31/2021	Atlantic Securities	Downgrade	Overweight ➝ Neutral	$390.00	High
3/2/2021	Barclays	Initiated Coverage	Underweight	$325.00	High
2/16/2021	BTIG Research	Boost Target	Buy	$410.00 ➝ $570.00	Low
2/12/2021	Piper Sandler	Boost Target	Overweight	$415.00 ➝ $510.00	Low
2/12/2021	Cowen	Boost Target	Outperform	$385.00 ➝ $460.00	Low
2/12/2021	SVB Leerink	Boost Target	Outperform	$360.00 ➝ $470.00	Low
12/22/2020	OTR Global	Upgrade	Positive		Medium
12/22/2020	Piper Sandler	Upgrade	Neutral ➝ Overweight	$340.00 ➝ $415.00	Medium
12/17/2020	BTIG Research	Upgrade	Neutral ➝ Buy	$410.00	Medium
12/16/2020	Smith Barney Citigroup	Boost Target		$330.00 ➝ $335.00	Low
12/7/2020	SVB Leerink	Boost Target	Positive ➝ Outperform	$325.00 ➝ $360.00	Low
12/1/2020	Argus	Lower Target		$380.00 ➝ $355.00	Low
10/30/2020	SVB Leerink	Boost Target	Outperform	$315.00 ➝ $325.00	High
10/13/2020	Guggenheim	Downgrade	Buy ➝ Neutral		Medium
9/30/2020	Atlantic Securities	Initiated Coverage	Overweight	$355.00 ➝ $355.00	Medium
9/29/2020	Wolfe Research	Downgrade	Outperform ➝ Peer Perform		Low
9/22/2020	Robert W. Baird	Lower Target	Neutral	$335.00 ➝ $281.00	Low
9/22/2020	SVB Leerink	Lower Target	Outperform	$360.00 ➝ $315.00	Low
9/22/2020	Stifel Nicolaus	Downgrade	Buy ➝ Hold	$380.00 ➝ $280.00	Low
9/22/2020	UBS Group	Downgrade	Buy ➝ Neutral	$390.00 ➝ $285.00	Low
9/21/2020	JPMorgan Chase & Co.	Downgrade	Overweight ➝ Neutral	$390.00 ➝ $280.00	Low
9/21/2020	Guggenheim	Upgrade	Neutral ➝ Buy	$345.00	High
9/11/2020	Argus	Reiterated Rating	Buy ➝ Reduce	$380.00 ➝ $380.00	Low
9/9/2020	Morgan Stanley	Initiated Coverage	Equal Weight	$400.00	Low
8/7/2020	SVB Leerink	Lower Target	Outperform	$370.00 ➝ $360.00	High
8/7/2020	Evercore ISI	Downgrade	In-Line ➝ Underperform	$310.00	High
8/7/2020	Piper Sandler	Downgrade	Overweight ➝ Neutral	$356.00 ➝ $340.00	High
7/7/2020	Guggenheim	Downgrade	Buy ➝ Neutral		Low
7/2/2020	JPMorgan Chase & Co.	Boost Target	Overweight	$340.00 ➝ $390.00	Low
5/21/2020	Argus	Boost Target		$340.00 ➝ $380.00	Low
5/1/2020	Piper Sandler	Lower Target	Positive ➝ Overweight	$370.00 ➝ $356.00	Low
5/1/2020	Wells Fargo & Company	Boost Target	Underweight	$245.00 ➝ $290.00	Low
5/1/2020	Stifel Nicolaus	Boost Target	Buy	$298.00 ➝ $325.00	High
5/1/2020	Cowen	Boost Target	Outperform	$275.00 ➝ $320.00	Medium
4/24/2020	Citigroup	Downgrade	Buy ➝ Neutral	$250.00 ➝ $320.00	Low
4/21/2020	Robert W. Baird	Downgrade	Outperform ➝ Neutral	$310.00	High
4/15/2020	Robert W. Baird	Lower Target	Outperform ➝ Outperform	$339.00 ➝ $310.00	Medium
4/2/2020	Stifel Nicolaus	Lower Target	Buy	$345.00 ➝ $298.00	Medium
3/30/2020	Wells Fargo & Company	Lower Target	Underweight	$290.00 ➝ $245.00	Medium
3/26/2020	Barclays	Lower Target	Overweight	$390.00 ➝ $350.00	High
3/20/2020	Citigroup	Lower Target	Buy	$350.00 ➝ $250.00	Low
2/4/2020	Credit Suisse Group	Reiterated Rating	Buy	$340.00	Low
1/30/2020	Wells Fargo & Company	Lower Target	Underweight	$300.00 ➝ $290.00	Low
1/30/2020	Citigroup	Lower Target	Buy	$385.00 ➝ $350.00	High
1/9/2020	Piper Sandler	Boost Target	Overweight	$341.00 ➝ $370.00	Low
1/7/2020	Wells Fargo & Company	Initiated Coverage	Underweight	$300.00	Medium
1/6/2020	Citigroup	Initiated Coverage	Buy	$385.00	Low
1/3/2020	UBS Group	Upgrade	Neutral ➝ Buy	$355.00	Medium
12/18/2019	Cowen	Reiterated Rating	Outperform	$320.00 ➝ $335.00	Medium
11/14/2019	Stifel Nicolaus	Initiated Coverage	Buy	$345.00	Medium
10/25/2019	Cowen	Set Target	Buy	$320.00	Low
10/25/2019	Wolfe Research	Set Target	Buy	$380.00	N/A
10/25/2019	Piper Sandler Companies	Lower Target	Overweight	$348.00 ➝ $341.00	High
10/25/2019	Guggenheim	Initiated Coverage	Buy ➝ Buy	$350.00 ➝ $350.00	High
9/27/2019	Piper Sandler Companies	Set Target	Buy	$348.00	Medium
9/25/2019	Argus	Boost Target	Buy	$300.00 ➝ $340.00	Medium
7/31/2019	Credit Suisse Group	Reiterated Rating	Buy	$340.00	Medium
7/30/2019	UBS Group	Boost Target	Buy	$350.00 ➝ $355.00	Low
7/30/2019	Piper Sandler Companies	Lower Target	Overweight	$382.00 ➝ $348.00	Low
7/18/2019	Argus	Lower Target	Buy	$340.00	Low
7/12/2019	Cowen	Lower Target	Outperform	$380.00 ➝ $320.00	Low
7/12/2019	Deutsche Bank Aktiengesellschaft	Lower Target	Hold	$290.00 ➝ $280.00	High
7/12/2019	Bank of America	Downgrade	Buy ➝ Underperform	$310.00	High
5/30/2019	Wolfe Research	Initiated Coverage	Outperform ➝ Outperform		Low

(Data available from 4/19/2019 forward)

News Sentiment Rating

0.78 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

20 very positive mentions
17 positive mentions
4 negative mentions
2 very negative mentions

Mentions as of

9/22/2023

25 very positive mentions
33 positive mentions
8 negative mentions
10 very negative mentions

Mentions as of

10/22/2023

6 very positive mentions
39 positive mentions
9 negative mentions
11 very negative mentions

Mentions as of

11/21/2023

17 very positive mentions
54 positive mentions
18 negative mentions
15 very negative mentions

Mentions as of

12/21/2023

28 very positive mentions
47 positive mentions
6 negative mentions
3 very negative mentions

Mentions as of

1/20/2024

26 very positive mentions
29 positive mentions
3 negative mentions
3 very negative mentions

Mentions as of

2/19/2024

30 very positive mentions
30 positive mentions
1 negative mentions
2 very negative mentions

Mentions as of

3/20/2024

29 very positive mentions
31 positive mentions
3 negative mentions
2 very negative mentions

Mentions as of

4/19/2024

Current Sentiment

Recent Stories by Sentiment

Illumina, Inc. offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest. It also provides whole-genome sequencing, genotyping, noninvasive prenatal testing, and product support services; and Galleri, a multi-cancer early detection test. In addition, the company is developing solutions to help accelerate cancer diagnoses, blood-based detection for minimal residual disease, and other post-diagnostic applications. The company serves genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. It markets and distributes its products directly to customers, as well as through life-science distributors. Illumina, Inc. was incorporated in 1998 and is based in San Diego, California.

Today's Range

Now: $116.69

$115.73

$119.15

50 Day Range

MA: $133.78

$116.69

$146.07

52 Week Range

Now: $116.69

$89.00

$232.23

Volume

1,810,235 shs

Average Volume

1,437,493 shs

Market Capitalization

$18.58 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.19

Frequently Asked Questions

What sell-side analysts currently cover shares of Illumina?: The following Wall Street sell-side analysts have issued research reports on Illumina in the last year: Bank of America Co., Barclays PLC, Canaccord Genuity Group Inc., Citigroup Inc., Credit Suisse Group AG, Evercore ISI, Guggenheim, HSBC Holdings plc, JPMorgan Chase & Co., OTR Global, Piper Sandler, Robert W. Baird, Royal Bank of Canada, Sanford C. Bernstein, Scotiabank, Stephens, Stifel Nicolaus, StockNews.com, TD Cowen, UBS Group AG, and Wolfe Research.
View the latest analyst ratings for ILMN.
What is the current price target for Illumina?: 20 Wall Street analysts have set twelve-month price targets for Illumina in the last year. Their average twelve-month price target is $167.70, suggesting a possible upside of 43.7%. Royal Bank of Canada has the highest price target set, predicting ILMN will reach $253.00 in the next twelve months. Barclays PLC has the lowest price target set, forecasting a price of $100.00 for Illumina in the next year.
View the latest price targets for ILMN.
What is the current consensus analyst rating for Illumina?: Illumina currently has 2 sell ratings, 9 hold ratings and 8 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in ILMN, but not buy more shares or sell existing shares.
View the latest ratings for ILMN.
What other companies compete with Illumina?: Other companies that are similar to Illumina include Waters, Revvity, Bruker, Mettler-Toledo International and Bio-Rad Laboratories. Learn More about companies similar to Illumina.
How do I contact Illumina's investor relations team?: Illumina's physical mailing address is 200 ILLUMINA WAY, SAN DIEGO CA, 92122. The life sciences company's listed phone number is (858) 202-4500 and its investor relations email address is [email protected]. The official website for Illumina is www.illumina.com. Learn More about contacing Illumina investor relations.

Illumina - ILMN Stock Price Target and Predictions

Analyst Price Target for ILMN

Current Consensus is Hold

Past Monthly Recommendations

Latest Recommendations

News Sentiment Rating

0.78 (Buy)

News Sentiment Over Time

Current Sentiment

Recent Stories by Sentiment

Very Negative

Negative

Positive

Very Positive

Today's Range

50 Day Range

52 Week Range

Volume

Average Volume

Market Capitalization

P/E Ratio

Dividend Yield

Beta

Frequently Asked Questions

What sell-side analysts currently cover shares of Illumina?

What is the current price target for Illumina?

What is the current consensus analyst rating for Illumina?

What other companies compete with Illumina?

How do I contact Illumina's investor relations team?